ANTIVIRAL DRUGS ADVISORY COMMITTEE
February 27, 2001
VALGANCICLOVIR NDA 21-304
Slides
NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis, Introduction, Debra Birnkrant, MD, FDA ppt
Approved Products for the Treatment of CMV Retinitis in Immunocompromised Patients, William Boyd, MD, FDA ppt
Sponsor Presentation
Set 3 ppt
FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS, Joseph Toerner, MD, FDA ppt
Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for DMV Retinitis, Robert O Kumi, PhD, FDA ppt